Stockreport

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF - Interim results indicate cognitive improvement in the active treatment group compared to placebo- No serious adverse events or deaths reported in the trial POTOMAC, [Read more]